Technology from medical device manufacturer Bedfont Scientific is being used in a novel study to see if nitric oxide (FeNO) levels are affected by Covid-19.
The UK company’s NObreath Fractional exhaled FeNO monitor is being used at the Hospital Policlin São José dos Campos in Brazil to establish what effect SARS-COV-2 (Covid-19) has on FeNO levels, and if measuring FeNO can act as a biomarker of prognosis for Covid-19 patients.
The study, conducted by Professor Rodolfo de Paula Vieira, uses the NObreath® FeNO monitor from Bedfont Scientific to take measurements during the initial consultation, together with other parameters.
... to continue reading you must be subscribed
